Stereotactic radiotherapy for ultra-central lung oligometastases in non-small-cell lung cancer
Cancers , Volume 12 - Issue 4
Background: Stereotactic body radiotherapy (SBRT) in ultra-central (UC) lung tumors, defined in the presence of planning target volume (PTV) overlap or direct tumor abutment to the central bronchial tree or esophagus, may be correlated to a higher incidence of severe adverse events. Outcome and toxicity in oligometastatic (≤3 metastases) non-small-cell lung cancer (NSCLC) patients receiving SBRT for UC tumors were evaluated. Methods: Oligometastatic NSCLC patients treated with SBRT for UC were retrospectively reviewed. Local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS) and overall survival (OS) were calculated. Incidence and grade of toxicity were evaluated. Statistical analysis was performed to assess the impact of clinical and treatment-related variables on outcome and toxicity occurrence. Results: Seventy-two patients were treated to a median biologically effective dose (BED) of 105 (75–132) Gy10 . Two-year LC, DMFS, PFS, and OS were 83%, 46%, 43%, and 49%. BED>75 Gy10 was correlated to superior LC (p = 0.02), PFS (p = 0.036), and OS (p < 0.001). Grade ≥3 toxicity rate was 7%, including one fatal esophagitis. No variables were correlated to DMFS or to occurrence of overall and grade ≥3 toxicity. Conclusions: SBRT using dose-intensive schedules improves outcome in NSCLC patients. Overall toxicity is acceptable, although rare but potentially fatal toxicities may occur.
|Biologically effective dose, Non-small-cell lung cancer, Oligometastases, Stereotactic radiotherapy, Ultra-central|
Loi, M, Franceschini, D. (Davide), Dominici, L. (Luca), Franzese, C. (Ciro), Chiola, I. (Ilaria), Comito, T. (Tiziana), … Scorsetti, M. (Marta). (2020). Stereotactic radiotherapy for ultra-central lung oligometastases in non-small-cell lung cancer. Cancers, 12(4). doi:10.3390/cancers12040885